POMDOCTOR LIMITED — Form 6-K Summary
Business context and reporting period
Filed October 2, 2026, by POMDOCTOR Limited, a foreign private issuer that files annual reports on Form 20-F. The filing reports results of the company’s September 30, 2026 extraordinary general meeting; it contains no operating or financial results.
Financial and operating information
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics. It provides no guidance or financial outlook.
Meeting results and material changes
- ADR program and Nasdaq listing: Shareholders approved on a non-binding advisory basis termination of the American Depositary Receipt program and direct listing of Class A ordinary shares on Nasdaq. The company proposed that both occur on the same date.
- Share consolidation: Shareholders approved a 10-for-1 consolidation of issued and unissued shares, also proposed to take effect on the same date as the ADR termination and listing. Fractional shares will be rounded up to the nearest whole share at the participant level.
- Authorized share capital: The approved amendment changes the authorized share count from 500,000,000 shares with par value US$0.0001 each to 50,000,000 shares with par value US$0.001 each. The filing lists 45,000,000 authorized Class A shares, 204,205 Class B shares, and 4,795,795 shares of other classes or classes to be determined by the board.
- Votes: The ADR proposal received 45,395,656 votes for, 34,398 against, and 519 abstentions. The consolidation proposal received 45,387,346 for, 39,999 against, and 3,228 abstentions. The filing says voting totals are based on voting power and exclude 7,639,947 discretionary proxies reported separately.
- A quorum was present. At the September 2, 2026 record date, 27,802,964 ordinary shares were outstanding, carrying 66,601,762 aggregate votes. The adjournment proposal was not presented because sufficient votes had been cast on the first two proposals.
Investor facts to verify
- Whether and when the ADR termination, direct Nasdaq listing, and share consolidation take effect.
- How the consolidation will be applied to individual holdings, including fractional-share rounding and the resulting share counts.
- The treatment and voting impact of the 7,639,947 discretionary proxies excluded from the reported proposal totals.